AC1MMYR2
MicroRNA-interfering drug.
Ren et al. previously found that a small molecule inhibitor of miR-21, termed AC1MMYR2, had the potential to impair tumorigenesis and metastases.
AC1MMYR2 attenuated CDK5 activity by functional targeting CDK5RAP1, CDK5 activator p39 and target p-FAK(ser732). A series of in vitro assays indicated that treatment of AC1MMYR2 combined with taxol suppressed tumor migration and invasion ability in both MDA-MB-231 and U87VIII cell. More importantly, combination therapy impaired high-dose taxol induced invadopodia, and EMT markers including beta-catenin, E-cadherin and vimentin. Strikingly, a significant reduction of lung metastases in mice was observed in the AC1MMYR2 plus taxol treatment 1).
1)
Ren Y, Zhou X, Yang JJ, Liu X, Zhao XH, Wang QX, Han L, Song X, Zhu ZY, Tian WP, Zhang L, Mei M, Kang CS. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastases by targeting miR-21/CDK5 axis. Cancer Lett. 2015 Jul 1;362(2):174-182. doi: 10.1016/j.canlet.2015.03.038. Epub 2015 Mar 28. PubMed PMID: 25827073.